Impact of macrolide therapy on mortality of HIV-infected patients with community-acquired pneumonia in a tertiary teaching hospital

Brazilian Journal of Infectious Diseases

Volumn 15, Issue 3, 2011, Pages 262-267

  Mello, Claudia Figueiredo ^a   Negra, Marinella Della ^b  

^a INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^b FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

Author keywords

HIV; Macrolides; Mortality; Pneumonia

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CLARITHROMYCIN; MACROLIDE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BREATHING RATE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; RETROSPECTIVE STUDY; TEACHING HOSPITAL; TREATMENT OUTCOME;

EID: 79959601930     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(11)70186-6     Document Type: Article

References (21)

1. Hull MW, Phillips P, Montaner JS. Changing global epidemiology of pulmonary manifestations of HIV/AIDS. Chest. 2008; 134(6):1287-98
2. Madeddu G, Fiori ML, Mura MS. Bacterial community-acquired pneumonia in HIV-infected patients. Curr Opin Pulm Med. 2010; 16(3):201-7.
3. Kohli R, Lo Y, Homel P et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis. 2006; 43(1):90-8.
4. Saindou M, Chidiac C, Miailhes P et al. Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods. HIV Med. 2008; 9(4):203-7.
5. Hefernan RT, Barrett NL, Gallagher KM et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis. 2005; 191(12):2038-45.
6. Park DR, Sherbin VL, Goodman MS et al. The etiology of community-acquired pneumonia at an urban public hospital: infuence of human Immunodeficiency virus infection and initial severity of illness. J Infect Dis. 2001; 184(3):268-77.
7. Feldman C, Klugman KP, Yu VL et al. Bacteraemic pneumo-coccal pneumonia: impact of HIV on clinical presentation and outcome. J Infect. 2007; 55(2):125-35.
8. Rodriguez-Barradas MC, Goulet J, Brown S et al. Impact of pneumococcal vaccination on the Incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis. 2008; 46(7):1093-100.
9. French N, Nakiyingi J, Carpenter LM et al. 23-valent pneu-mococcal polysaccharide vaccine in HIV-1-infected Uganda adults: doble-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11.
10. Curran A, Falcó V, Crespo M et al. Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome. HIV Med. 2008; 9(8):609-15.
11. Corrêa RA, Lundgren FLC, Pereira-Silva JL et al. Diretrizes bra-sileiras para pneumonia adquirida na comunidade em adultos imunocompetentes - 2009. J Bras Pneumol. 2009; 35(6):574-601.
12. Metersky ML, Ma A, Houck PM, Bratzler D W. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fuoroquinolones. Chest. 2007; 131(2):466-73.
13. Baddour LM, Yu VL, Klugman KP et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004; 170(4):440-4.
14. Martínez JA, Horcajada J P, Almela M et al. Addition of a mac-rolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003; 36(4):389-95.
15. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009; 33(1):153-9.
16. Amsden G W. Anti-infammatory efects of macrolides-an underappreciated beneft in the treatment of community-acquired respiratory tract infections and chronic infamma-tory pulmonary conditions? J Antimicrob Chemother. 2005; 55(1):10-21.
17. Culi- O, Erakovi- V, Cepelak I et al. Azithromycin modulates neutrophil function and circulating infammatory mediators in healthy human subjects. Eur J Pharmacol. 2002; 450(3):277-89.
18. Anderson R, Steel HC, Cockeran R et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycy-cline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J An-timicrob Chemother. 2007; 60(5):1155-8.
19. Ellis M, Gupta S, Galant S et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis. 1988; 158(6):1268-76.
20. Kuritzkes DR. Neutropenia, Neutrophil Dysfunction, and Bacterial Infection in Patients with Human Immunodeficiency Virus Disease: The Role of Granulocyte Colony-Stimulating Factor. Clin Infect Dis. 2000; 30(2):256-60.
21. Pitrak DL. Apoptosis and its Role in Neutrophil Dysfunction in AIDS. Oncologist 1997; 2(2):121-4.